The Resource Drugs affecting lipid metabolism : proceedings of the XIV International Symposium held in New York, US, September 9-12, 2001, chaired by A.M. Gotto, Jr., and R. Paoletti

Drugs affecting lipid metabolism : proceedings of the XIV International Symposium held in New York, US, September 9-12, 2001, chaired by A.M. Gotto, Jr., and R. Paoletti

Label
Drugs affecting lipid metabolism : proceedings of the XIV International Symposium held in New York, US, September 9-12, 2001
Title
Drugs affecting lipid metabolism
Title remainder
proceedings of the XIV International Symposium held in New York, US, September 9-12, 2001
Statement of responsibility
chaired by A.M. Gotto, Jr., and R. Paoletti
Creator
Contributor
Subject
Genre
Language
eng
Member of
Cataloging source
MMU
Index
no index present
Literary form
non fiction
http://bibfra.me/vocab/lite/meetingDate
2001
http://bibfra.me/vocab/lite/meetingName
International Symposium on Drugs Affecting Lipid Metabolism
http://library.link/vocab/relatedWorkOrContributorName
  • Paoletti, Rodolfo
  • Gotto, Antonio M.
  • Medicom International Incorporated
Series statement
International journal of clinical practice
Series volume
supplement 124, February 2002
http://library.link/vocab/subjectName
  • Arteriosclerosis
  • Fluorobenzenes
  • Hypolipidemic Agents
  • Lipid Metabolism
  • Lipoproteins
  • Metabolism
Label
Drugs affecting lipid metabolism : proceedings of the XIV International Symposium held in New York, US, September 9-12, 2001, chaired by A.M. Gotto, Jr., and R. Paoletti
Instantiates
Publication
Note
Cover title
Carrier category
volume
Carrier category code
  • nc
Carrier MARC source
rdacarrier
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
Rosuvastatin: kinetics of inhibition of HMG-CoA reductase -- HMG-COA reductase inhibition decreases caveolin-1 independently of plasma lipid lowering in heart and blood vessels of ApoE(-l-) mice -- Rosuvastatin inhibits monocyte/endothelial interactions in APoE(-l-) mice -- Rosuvastatin diminishes myocardial injury after ischemia/reperfusion -- Rosuvastatin reduces MMP-9 and MMP-7 secretion by human monocyte-derived macrophages -- Rosuvastatin normalises atherogenic levels of ApoB-containing lipoprotein subfractions -- Effect of rosuvastatin on high density lipoprotein cholesterol and apolipoprotein A-1 in patients with heterozygous familial hypercholesterolemia -- Effects of rosuvastatin on serum lipids and lipid subfractions in patients with hypertriglyceridemia -- 52-week trial of rosuvastatin versus atorvastatin in patients with primary hyperclolesterolemia -- 52-week trial of rosuvastatin versus pravastatin and simvastatin in patients with primary hypercholesterolemia -- Rosuvastatin alone produces similar lipid benefits compared with rosuvastatin plus cholestyramine in patients with primary hypercholesterolemia -- Beneficial effects of combination therapy with rosuvastatin and extended-release niacin in patients with a mixed dislipidemia -- Review of the safety profile of rosuvastatin in an international phase II/III clinical trial programme
Control code
49554342
Dimensions
28 cm
Extent
15 pages
Media category
unmediated
Media MARC source
rdamedia
Media type code
  • n
Label
Drugs affecting lipid metabolism : proceedings of the XIV International Symposium held in New York, US, September 9-12, 2001, chaired by A.M. Gotto, Jr., and R. Paoletti
Publication
Note
Cover title
Carrier category
volume
Carrier category code
  • nc
Carrier MARC source
rdacarrier
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
Rosuvastatin: kinetics of inhibition of HMG-CoA reductase -- HMG-COA reductase inhibition decreases caveolin-1 independently of plasma lipid lowering in heart and blood vessels of ApoE(-l-) mice -- Rosuvastatin inhibits monocyte/endothelial interactions in APoE(-l-) mice -- Rosuvastatin diminishes myocardial injury after ischemia/reperfusion -- Rosuvastatin reduces MMP-9 and MMP-7 secretion by human monocyte-derived macrophages -- Rosuvastatin normalises atherogenic levels of ApoB-containing lipoprotein subfractions -- Effect of rosuvastatin on high density lipoprotein cholesterol and apolipoprotein A-1 in patients with heterozygous familial hypercholesterolemia -- Effects of rosuvastatin on serum lipids and lipid subfractions in patients with hypertriglyceridemia -- 52-week trial of rosuvastatin versus atorvastatin in patients with primary hyperclolesterolemia -- 52-week trial of rosuvastatin versus pravastatin and simvastatin in patients with primary hypercholesterolemia -- Rosuvastatin alone produces similar lipid benefits compared with rosuvastatin plus cholestyramine in patients with primary hypercholesterolemia -- Beneficial effects of combination therapy with rosuvastatin and extended-release niacin in patients with a mixed dislipidemia -- Review of the safety profile of rosuvastatin in an international phase II/III clinical trial programme
Control code
49554342
Dimensions
28 cm
Extent
15 pages
Media category
unmediated
Media MARC source
rdamedia
Media type code
  • n

Library Locations

    • J. Otto Lottes Health Sciences LibraryBorrow it
      1 Hospital Dr, Columbia, MO, 65201, US
      38.939544 -92.328377
Processing Feedback ...